[F:1][C:2]1([F:27])[C:4]2([C:11]3[N:16]=[C:15]4[N:17]([CH3:26])[C:18](=[O:25])[N:19]([CH2:20][C:21]([CH3:24])([CH3:23])[CH3:22])[C:14]4=[CH:13][CH:12]=3)[CH2:5][CH:6]3[CH:10]([CH:3]12)[CH2:9][NH:8][CH2:7]3.[O:28]1[CH:32]=[CH:31][C:30]([C:33](O)=[O:34])=[N:29]1.CCN(C(C)C)C(C)C.CN(C(ON1N=NC2C=CC=NC1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F>C(#N)C>[F:27][C:2]1([F:1])[C:4]2([C:11]3[N:16]=[C:15]4[N:17]([CH3:26])[C:18](=[O:25])[N:19]([CH2:20][C:21]([CH3:24])([CH3:22])[CH3:23])[C:14]4=[CH:13][CH:12]=3)[CH2:5][CH:6]3[CH:10]([CH:3]12)[CH2:9][N:8]([C:33]([C:30]1[CH:31]=[CH:32][O:28][N:29]=1)=[O:34])[CH2:7]35-(4,4-Difluorooctahydro-4aH-cyclopropa[3,4]cyclopenta[1,2-c]pyrrol-4a-yl)-1-(2,2-dimethylpropyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (30-3, 50 mg, 0.14 mmol, 1.0 equiv), isoxazole-3-carboxylic acid (2-6, 22.5 mg, 0.20 mmol, 1.5 equiv), DIPEA (0.070 mL, 0.40 mmol, 3.0 equiv) and HATU (76 mg, 0.20 mmol, 1.5 equiv) were added to anhydrous acetonitrile (1 mL). After stirring for 10 min at room temperature, LCMS showed consumption of starting material. Purification by reverse-phase HPLC (20-100% CH3CN:0.1% TFA in H2O) provided 30-4 as a white solid. MS m/z (M+H): calculated=472.2155; observed=472.2153.
Loading…